Emergent Biosolutions (NYSE:EBS) Sets New 12-Month Low at $39.41

Share on StockTwits

Emergent Biosolutions Inc (NYSE:EBS) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $39.41 and last traded at $39.45, with a volume of 7854 shares trading hands. The stock had previously closed at $40.80.

Several research firms have commented on EBS. ValuEngine cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 target price on shares of Emergent Biosolutions in a research note on Thursday, May 2nd. Wells Fargo & Co cut their target price on Emergent Biosolutions to $61.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Finally, Cowen restated a “hold” rating and issued a $60.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $70.33.

The stock has a market cap of $2.11 billion, a P/E ratio of 17.42, a PEG ratio of 0.67 and a beta of 1.60. The company has a 50 day simple moving average of $43.39 and a 200 day simple moving average of $49.08. The company has a current ratio of 2.30, a quick ratio of 1.53 and a debt-to-equity ratio of 0.84.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The firm had revenue of $243.20 million during the quarter, compared to the consensus estimate of $217.94 million. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The company’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.07 EPS. As a group, sell-side analysts expect that Emergent Biosolutions Inc will post 3.05 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EBS. Rehmann Capital Advisory Group increased its holdings in shares of Emergent Biosolutions by 303.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 1,034 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 778 shares during the last quarter. BlackRock Inc. grew its holdings in Emergent Biosolutions by 2.3% in the 2nd quarter. BlackRock Inc. now owns 6,891,631 shares of the biopharmaceutical company’s stock valued at $332,936,000 after buying an additional 155,055 shares in the last quarter. Private Capital Group LLC grew its holdings in Emergent Biosolutions by 11.1% in the 2nd quarter. Private Capital Group LLC now owns 2,397 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 239 shares in the last quarter. Susquehanna International Group LLP grew its holdings in Emergent Biosolutions by 272.5% in the 2nd quarter. Susquehanna International Group LLP now owns 58,115 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 42,515 shares in the last quarter. Finally, Bamco Inc. NY grew its holdings in Emergent Biosolutions by 80.6% in the 2nd quarter. Bamco Inc. NY now owns 195,000 shares of the biopharmaceutical company’s stock valued at $9,420,000 after buying an additional 87,000 shares in the last quarter. Hedge funds and other institutional investors own 87.48% of the company’s stock.

Emergent Biosolutions Company Profile (NYSE:EBS)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

See Also: What are the disadvantages of after-hours trading?

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.